The U.S. Food and Drug Administration (FDA) announced it will accelerate the review process for psychedelic-based mental health treatments developed by Compass Pathways, the Usona Institute, and Transcend Therapeutics.
This move aligns with the Trump administration’s broader strategy to improve access to these emerging therapies, which remain controversial despite their potential benefits.
The agency will issue priority review vouchers for three specific treatments:
- Compass Pathways’ psilocybin for treatment-resistant depression;
- Usona Institute’s psilocybin for major depressive disorder;
- Transcend Therapeutics’ MDMA-like treatment for post-traumatic stress disorder (PTSD).
The FDA confirmed the medications receiving vouchers but did not initially disclose the developers. Compass Pathways later confirmed its receipt of a voucher, while the other companies were identified by an anonymous source familiar with the matter.
Related articles
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
Kratom Use Surges in the US: Rising Addiction and Mental Health Concerns
A national study of kratom use in the US found rising popularity among young adults, and it is linked to addiction and mental health issues, according...
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Mail-Order Abortion Pills Remain Legal Amid Legal Uncertainty
In a discussion about the best fruits, my STAT colleague Alexa Lee and I agreed that peaches have been mid in recent years. Is this just a New York Ci...
FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
Supreme Court Blocks Restrictions on Abortion Pill Mifepristone, Ensuring Continued Access
WASHINGTON — The Supreme Court on Thursday preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restri...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
Who Will Lead the FDA Next? The Search for a New Commissioner Heats Up
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to...